modified GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-21. Numbers and descriptions here follow the published literature rather than marketing material.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
=== Swimming and undulatory locomotion === The skin of these animal that use undulatory motion to locomote have several distinct characteristics. The skin of these animals consists of cross-helical arrangement of collagen and elastin fibers embedded in the dermal layer of skin, a two-dimensional stiffness. which permits bending at small curvatures and resists bending at high curvatures and skin is attached directly to the underlying muscles. Fish, shark, and snakes are all examples of animals that locomote using undulatory locomotion.
== Etymology and central beliefs == Effective accelerationism, a portmanteau of "effective altruism" and "accelerationism", is a fundamentally techno-optimist movement. According to Guillaume Verdon, one of the movement's founders, its aim is for human civilization to "clim[b] the Kardashev gradient", meaning its purpose is for human civilization to rise to next levels on the Kardashev scale by maximizing energy usage. To achieve this goal, effective accelerationism wants to accelerate technological progress. It is strongly focused on artificial general intelligence (AGI), because it sees AGI as fundamental for climbing the Kardashev scale. The movement therefore advocates for unrestricted development and deployment of artificial intelligence. Regulation of artificial intelligence and government intervention in markets more generally is met with opposition. Many of its proponents have libertarian views and think that AGI will be most aligned if many AGIs compete against each other on the marketplace. The founders of the movement see it as rooted in Jeremy England's theory on the origin of life, which is focused on entropy and thermodynamics. According to them, the universe aims to increase entropy, and life is a way of increasing it. By spreading life throughout the universe and making life use up ever increasing amounts of energy, the universe's purpose would thus be fulfilled.
== Mechanism of action == Strychnine is a neurotoxin which acts as an antagonist of glycine and acetylcholine receptors. It primarily affects the motor nerve fibers in the spinal cord which control muscle contraction. An impulse is triggered at one end of a nerve cell by the binding of neurotransmitters to the receptors. In the presence of an inhibitory neurotransmitter, such as glycine, a greater quantity of excitatory neurotransmitters must bind to receptors before an action potential is generated. Glycine acts primarily as an agonist of the glycine receptor, which is a ligand-gated chloride channel in neurons located in the spinal cord and in the brain. This chloride channel allows the negatively charged chloride ions into the neuron, causing a hyperpolarization which pushes the membrane potential further from threshold. Strychnine is an antagonist of glycine; it binds noncovalently to the same receptor, preventing the inhibitory effects of glycine on the postsynaptic neuron. Therefore, action potentials are triggered with lower levels of excitatory neurotransmitters. When the inhibitory signals are prevented, the motor neurons are more easily activated and the victim has spastic muscle contractions, resulting in death by asphyxiation. Strychnine binds the Aplysia californica acetylcholine binding protein (a homolog of nicotinic receptors) with high affinity but low specificity, and does so in multiple conformations.
Sources: en.wikipedia.org
Robert Fripp – guitar, keyboards, Mellotron, electronics (1968–1974, 1981–1984, 1994–2008, 2013–2021) Mel Collins – saxophones, flute, bass flute, clarinet, bass clarinet, Mellotron, backing vocals (1970–1972, 2013–2021) Tony Levin – bass guitar, Chapman Stick, upright bass, synthesisers, backing vocals (1981–1984, 1994–1999, 2003–2008, 2013–2021) Pat Mastelotto – drums, percussion, programming (1994–2008, 2013–2021) Gavin Harrison – drums, percussion (2007–2008, 2013–2021) Jakko Jakszyk – lead vocals, guitar, flute, keyboards (2013–2021) Jeremy Stacey – drums, keyboards, backing vocals (2016–2021)
=== Effects of climate change === The effects of climate change on tea crops have been widely investigated and include yield losses, negative effects on regional economies, and changes in tea taste, aroma, texture, colour that affect market prices, and consumer demand. Climate change affects the quantity of tea farmers are able to grow by influencing precipitation levels, increasing temperatures, encouraging insect pests, and shifting the timing of growing seasons. This happens differently in different regions. China and India—two of the largest producers—are both experiencing shorter growing seasons, heatwaves, and exposure of crops to hot spells. To reduce the effects of climate change, tea famers are turning to agroforestry, soil enrichment through the incorporation of legumes, growing tea plants from seed, soil conservation methods, and new varieties of tea that have adaptations. Additional research is needed to explore the synergistic effects of multiple climate stressors on tea and in underrepresented regions such as Africa and Southeast Asia. To further the research agenda, scholars note the importance of emerging molecular technologies and information tools for modelling and simulation. Agroforestry and modern technologies for soil management "can improve nitrogen use efficiency, reduce greenhouse gas emissions, and support sustainable tea cultivation" alongside socioeconomic research to ensure farmers can access such technologies and remain economically viable.
=== Therapeutic === Activation of the NRF2 (nuclear factor erythroid 2–related factor 2) pathway has been explored as a therapeutic strategy due to its role in regulating antioxidant and cytoprotective responses. One of the most clinically advanced NRF2 activators is dimethyl fumarate, marketed as Tecfidera by Biogen Idec. It was approved by the Food and Drug Administration in March 2013 following a successful Phase III clinical trial that demonstrated reduced relapse rates and delayed progression of disability in individuals with multiple sclerosis. Although the precise mechanism of action of dimethyl fumarate is not fully understood, it is known to activate the NRF2 signaling pathway. Both dimethyl fumarate and its active metabolite, monomethyl fumarate, promote NRF2 nuclear translocation and the subsequent transcription of antioxidant response element (ARE)-driven genes. In addition, they have been shown to act as nicotinic acid receptor agonists in vitro. Despite its clinical efficacy, dimethyl fumarate is associated with several adverse effects, including anaphylaxis, angioedema, progressive multifocal leukoencephalopathy (PML), lymphopenia, and liver damage. Common side effects include flushing and gastrointestinal symptoms such as diarrhea, nausea, and upper abdominal pain. Other NRF2 activators have also been investigated. The dithiolethiones are a class of organosulfur compounds known to induce NRF2 activity. Among them, oltipraz is the most extensively studied.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.